Related Experiment Video
Updated: Apr 16, 2026
06:15
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
28.0K
Treating recurrent glioblastoma: an update.
Carlos Kamiya-Matsuoka1, Mark R Gilbert
1Department of Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
CNS Oncology
|March 14, 2015
Summary
Recurrent glioblastoma presents significant challenges due to its heterogeneity and limited effective salvage therapies. Future research needs improved imaging and biomarkers for better treatment response assessment.
Area of Science:
- Neuro-oncology
- Cancer Biology
- Translational Medicine
Background:
- Glioblastoma is an aggressive brain tumor with high recurrence and mortality rates.
- Tumor molecular heterogeneity and phenotypic plasticity contribute to poor prognosis.
- Current salvage therapies for recurrent glioblastoma are limited in efficacy.
Purpose of the Study:
- To review recent therapeutic approaches for recurrent glioblastoma.
- To discuss future perspectives in treating this challenging condition.
Main Methods:
- Literature review of recent studies on recurrent glioblastoma treatment.
- Analysis of challenges including molecular heterogeneity and imaging confounders.
Main Results:
- Despite advances, translating molecular biology insights into effective treatments remains difficult.
- Tumor recurrence is nearly universal, with few established salvage regimens.
- Increasing molecular heterogeneity, both sporadic and treatment-induced, complicates treatment.
Conclusions:
- Novel clinical trial designs are needed to test new regimens and drug delivery strategies.
- Development of precise imaging techniques and reliable surrogate markers is crucial for assessing treatment response.
- Addressing heterogeneity and improving treatment strategies are key for managing recurrent glioblastoma.
